Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects
Abstract Resveratrol is widely used in the fields of medicine and health supplements; however, its poor stability and low relative bioavailability limit its applications. This study aimed to compare the plasma drug concentrations and key pharmacokinetic parameters of two resveratrol solid formulatio...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-08665-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344338705776640 |
|---|---|
| author | Jing Wang Tingting Liu Peiru Chen Dongli Yin Haijun Zhang Xiang Qiu Shengcan Zou Weiyong Li |
| author_facet | Jing Wang Tingting Liu Peiru Chen Dongli Yin Haijun Zhang Xiang Qiu Shengcan Zou Weiyong Li |
| author_sort | Jing Wang |
| collection | DOAJ |
| description | Abstract Resveratrol is widely used in the fields of medicine and health supplements; however, its poor stability and low relative bioavailability limit its applications. This study aimed to compare the plasma drug concentrations and key pharmacokinetic parameters of two resveratrol solid formulations, T1 and T2. A single-center, randomized, open-label, two-formulation, single-dose, two-period, crossover trial was conducted involving 12 healthy subjects. Blood samples were collected after a single dose for pharmacokinetic (PK) analysis, including Cmax, AUC0 − t, AUC0−∞, Tmax, and T1/2. The concentrations of resveratrol and its metabolites in human plasma were determined using HPLC-MS/MS. The results showed for total resveratrol, the Cmax of T1 was 4.8 times higher than that of T2, while the AUC0 − t of T1 was 1.7 times that of T2. The Tmax of T1 was also markedly shorter, whereas the t1/2 of T2 was slightly longer than that of T1. This suggests that T1 demonstrated superior absorption extent and rate, with overall pharmacokinetic performance surpassing that of T2. In addition, all drugs were well tolerated, no severe adverse reactions occurred. In conclusion, following single-dose oral administration of the two resveratrol formulations, T1 and T2, both formulations were demonstrating good safety profiles. Compared to T2, the modified formulation of T1 significantly enhanced the absorption rate, extent, and relative bioavailability of resveratrol. The test formulation T1 was overall superior to the test formulation T2. |
| format | Article |
| id | doaj-art-5008391175894e949fb33594a7f6f55c |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-5008391175894e949fb33594a7f6f55c2025-08-20T03:42:41ZengNature PortfolioScientific Reports2045-23222025-07-0115111110.1038/s41598-025-08665-0Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjectsJing Wang0Tingting Liu1Peiru Chen2Dongli Yin3Haijun Zhang4Xiang Qiu5Shengcan Zou6Weiyong Li7Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyQingdao Chenland Pharmaceutical Co., LtdDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyQingdao Chenland Pharmaceutical Co., LtdQingdao Chenland Pharmaceutical Co., LtdQingdao Chenland Pharmaceutical Co., LtdQingdao Chenland Pharmaceutical Co., LtdDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Resveratrol is widely used in the fields of medicine and health supplements; however, its poor stability and low relative bioavailability limit its applications. This study aimed to compare the plasma drug concentrations and key pharmacokinetic parameters of two resveratrol solid formulations, T1 and T2. A single-center, randomized, open-label, two-formulation, single-dose, two-period, crossover trial was conducted involving 12 healthy subjects. Blood samples were collected after a single dose for pharmacokinetic (PK) analysis, including Cmax, AUC0 − t, AUC0−∞, Tmax, and T1/2. The concentrations of resveratrol and its metabolites in human plasma were determined using HPLC-MS/MS. The results showed for total resveratrol, the Cmax of T1 was 4.8 times higher than that of T2, while the AUC0 − t of T1 was 1.7 times that of T2. The Tmax of T1 was also markedly shorter, whereas the t1/2 of T2 was slightly longer than that of T1. This suggests that T1 demonstrated superior absorption extent and rate, with overall pharmacokinetic performance surpassing that of T2. In addition, all drugs were well tolerated, no severe adverse reactions occurred. In conclusion, following single-dose oral administration of the two resveratrol formulations, T1 and T2, both formulations were demonstrating good safety profiles. Compared to T2, the modified formulation of T1 significantly enhanced the absorption rate, extent, and relative bioavailability of resveratrol. The test formulation T1 was overall superior to the test formulation T2.https://doi.org/10.1038/s41598-025-08665-0ResveratrolClinical trialsPharmacokinetics |
| spellingShingle | Jing Wang Tingting Liu Peiru Chen Dongli Yin Haijun Zhang Xiang Qiu Shengcan Zou Weiyong Li Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects Scientific Reports Resveratrol Clinical trials Pharmacokinetics |
| title | Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects |
| title_full | Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects |
| title_fullStr | Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects |
| title_full_unstemmed | Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects |
| title_short | Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects |
| title_sort | pharmacokinetic evaluation of two oral resveratrol formulations in a randomized open label crossover study in healthy fasting subjects |
| topic | Resveratrol Clinical trials Pharmacokinetics |
| url | https://doi.org/10.1038/s41598-025-08665-0 |
| work_keys_str_mv | AT jingwang pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects AT tingtingliu pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects AT peiruchen pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects AT dongliyin pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects AT haijunzhang pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects AT xiangqiu pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects AT shengcanzou pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects AT weiyongli pharmacokineticevaluationoftwooralresveratrolformulationsinarandomizedopenlabelcrossoverstudyinhealthyfastingsubjects |